Holen Sie sich die Stockscreener-App
1.21
3.42%
0.04
Schlusskurs vom Vortag:
$1.17
Offen:
$1.16
24-Stunden-Volumen:
86,084
Relative Volume:
0.01
Marktkapitalisierung:
$3.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.38M
KGV:
-0.0436
EPS:
-27.73
Netto-Cashflow:
$-12.72M
1W Leistung:
+6.14%
1M Leistung:
-26.22%
6M Leistung:
+40.09%
1J Leistung:
-76.13%
1-Tages-Spanne:
$1.15
$1.24
1-Wochen-Bereich:
$1.01
$1.24
52-Wochen-Spanne:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Firmenname
Windtree Therapeutics Inc
Sektor
Branche
Telefon
(215) 488-9300
Adresse
2600 KELLY ROAD, WARRINGTON, PA
Vergleichen Sie WINT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
1.21 | 3.84M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-26 | Eingeleitet | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Aktie (WINT) Neueste Nachrichten
Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments - MSN
Windtree Therapeutics announces board member resignation By Investing.com - Investing.com Nigeria
Windtree Therapeutics announces board member resignation - Investing.com Australia
Windtree Therapeutics (WINT) Advances Clinical and Strategic Ini - GuruFocus
Windtree Therapeutics Reports 2024 Progress and Strategy Shift - TipRanks
WINDTREE THERAPEUTICS INC /DE/ SEC 10-K Report - TradingView
Windtree Therapeutics reports FY24 EPS ($104.35) vs. ($4,718.84) last year - TipRanks
Windtree Therapeutics sees cash runway through April - TipRanks
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates - TradingView
Company Secures Additional Funding to Sustain Operations Through April 2025 | WINT Stock News - GuruFocus
Windtree Slashes Losses by $18.5M as Cardiogenic Shock Drug Shows Promise - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest - Defense World
Windtree Therapeutics Issues Convertible Notes to Raise $250,000 - Investing.com Australia
Windtree Therapeutics (WINT) to Release Earnings on Tuesday - Defense World
Windtree Therapeutics Delays Annual Report Filing - TipRanks
WINT stock touches 52-week low at $1.32 amid steep annual decline - Investing.com
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest - Defense World
Windtree Therapeutics Regains Nasdaq Compliance - MSN
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Windtree reports positive Phase 2b study on heart failure therapy - MSN
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cos - GuruFocus
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - Marketscreener.com
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Windtree Therapeutics Inc. (WINT) Soars 14.63% on Nasdaq Compliance - AInvest
Massive 60% Cost Cut: How PHEXXI's New Deal Transforms Global Contraceptive Access - Stock Titan
Windtree Therapeutics IncOn March 20, Entered License And Supply Agreement With Evofem BiosciencesSEC Filing - MarketScreener
Windtree Therapeutics regains compliance with Nasdaq listing rules - TipRanks
Windtree Therapeutics Regains Compliance With Nasdaq Listing Rules For Continued Listing - Nasdaq
Windtree Therapeutics Regains Nasdaq Compliance Over Minimum Share Price Rule - MarketScreener
Windtree Therapeutics regains Nasdaq compliance - Investing.com India
Evofem Reports Fourth Consecutive Year of Net Sales Growth - Quantisnow
Evofem Posts Record 4th Year Growth: Revenue Up 6% as Operating Costs Plunge 27% - Stock Titan
Windtree Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - The Manila Times
Windtree Therapeutics Dodges Delisting: How The Biotech Company Saved Its Nasdaq Status - Stock Titan
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Biotech Stocks To Consider – March 20th - Defense World
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI® - MSN
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Windtree shares rise as it announces agreement to become sourcing partner for Evofem - MSN
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
Windtree Therapeutics (WINT) Climb Amid New Licensing Deal - Stocks Telegraph
Another Day, Another Biotech Ripping Before The Bell - The Globe and Mail
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results - Benzinga
What's Going On With Windtree Therapeutics Shares Thursday? - Benzinga
Windtree to become sourcing partner for Evofem Biosciences - TipRanks
Windtree Signs Deal to Become Sourcing Partner for Evofem's Contraceptive Vaginal Gel; Shares Rise - Marketscreener.com
Windtree partners with Evofem for contraceptive gel supply - Investing.com
Windtree's Game-Changing Deal: Manufacturing Rights to $19M FDA-Approved Contraceptive - Stock Titan
Finanzdaten der Windtree Therapeutics Inc-Aktie (WINT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):